INDIANPOLIS, Ind. — CoLucid Pharmaceuticals, a startup backed by Pappas Ventures in Research Triangle Park, has added a Dynogen Pharmaceuticals to its management team.
Nadia Rupniak will lead project and alliance management for CoLucid. She led project management at Dynogen. Dynogen recently sold its research and development facility in Durham to a Japanese firm.
Pappas is an investor in Dynogen, having provided seed funding. Pappas and Domain Associates led the $16.5 million A round in financing raised by CoLucid earlier this year.
CoLucid also named James White, a former executive with Eli Lily, as its chief executive officer.
CoLucid is developing new treatments for migraine headaches, pain and neurological disorders. The company has licensed a clinical stage compound from Eli for treatment of migraine. CoLucid also acquired a chemistry development platform from another firm.
“The investors are pleased to have recruited an executive with Jim’s relevant experiences and leadership capabilities to lead CoLucid,” said Art Pappas, chairman of the CoLucid board and managing partner of Pappas Ventures. “Jim and his team have the experience to move this company forward in its growth and development.”
Pappas was the founding CEO for CoLucid.
Alison Pilgrim, chief medical officer of CoLucid, is a former Glaxo executive.
CoLucid: www.colucid.com
